Deadline
Passed
Lead Plaintiff Deadline: July 20, 2021
Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
02
Nov 2020
08
Apr 2021
(i) the teplizumab Biologics License Application (“BLA”) was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA’s approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Provention Bio purchased during the class period listed above.
If you suffered a loss in Provention Bio during the relevant time frame, you have until July 20, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.